Looking Closely at the Growth Curve for Castle Biosciences Inc. (CSTL) – News Heater
Home  »  Trending   »  Looking Closely at the Growth Curve for Castle Bio...

Looking Closely at the Growth Curve for Castle Biosciences Inc. (CSTL)

Castle Biosciences Inc. (NASDAQ:CSTL) went up by 23.31% from its latest closing price compared to the recent 1-year high of $78.92. The company’s stock price has collected 30.37% of gains in the last five trading sessions.

Is It Worth Investing in Castle Biosciences Inc. (NASDAQ :CSTL) Right Now?

Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Castle Biosciences Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $48.29, which is $26.18 above the current price. CSTL currently public float of 24.96M and currently shorts hold a 5.08% ratio of that float. Today, the average trading volume of CSTL was 388.38K shares.

CSTL’s Market Performance

CSTL stocks went up by 30.37% for the week, with a monthly jump of 2.93% and a quarterly performance of -49.31%, while its annual performance rate touched -70.39%. The volatility ratio for the week stands at 9.86% while the volatility levels for the past 30 days are set at 7.98% for Castle Biosciences Inc. The simple moving average for the period of the last 20 days is 13.37% for CSTL stocks with a simple moving average of -48.14% for the last 200 days.

Analysts’ Opinion of CSTL

Many brokerage firms have already submitted their reports for CSTL stocks, with Stephens repeating the rating for CSTL by listing it as a “Overweight.” The predicted price for CSTL in the upcoming period, according to Stephens is $59 based on the research report published on January 07th of the current year 2022.

Lake Street, on the other hand, stated in their research note that they expect to see CSTL reach a price target of $94. The rating they have provided for CSTL stocks is “Buy” according to the report published on April 30th, 2021.

KeyBanc Capital Markets gave a rating of “Overweight” to CSTL, setting the target price at $70 in the report published on November 10th of the previous year.

CSTL Trading at 3.33% from the 50-Day Moving Average

After a stumble in the market that brought CSTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.98% of loss for the given period.

Volatility was left at 7.98%, however, over the last 30 days, the volatility rate increased by 9.86%, as shares surge +9.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.49% lower at present.

During the last 5 trading sessions, CSTL rose by +30.37%, which changed the moving average for the period of 200-days by -71.21% in comparison to the 20-day moving average, which settled at $19.60. In addition, Castle Biosciences Inc. saw -48.43% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CSTL starting from BRADBURY DANIEL, who sale 8,852 shares at the price of $44.93 back on Mar 30. After this action, BRADBURY DANIEL now owns 97,537 shares of Castle Biosciences Inc., valued at $397,680 using the latest closing price.

BRADBURY DANIEL, the Director of Castle Biosciences Inc., sale 8,852 shares at $45.32 during a trade that took place back on Mar 29, which means that BRADBURY DANIEL is holding 100,037 shares at $401,129 based on the most recent closing price.

Stock Fundamentals for CSTL

Current profitability levels for the company are sitting at:

  • -42.60 for the present operating margin
  • +80.07 for the gross margin

The net margin for Castle Biosciences Inc. stands at -33.26. Equity return is now at value -12.60, with -11.60 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 14.21.

Is Bitfarms Ltd. (BITF) a Keeper?

Bitfarms Ltd. (NASDAQ:BITF) went down by -7.33% from its latest closing price compared to the recent 1-year high of $9.36. The company’s stock price has